• Companies benefit from energy efficiency wizardry

    More efficient use of energy can save companies money and make an important contribution to reducing global warming. To achieve these savings, the ITEA Cluster project SPEAR involving 22 international partners and led by southwest German software developer, Let’s Dev, has created and tested an algorithm to assess the sum of a company’s energy usage by looking at all individual devices. It can also suggest sustainable energy savings and ways to use more renewable sources like solar and wind energy.

  • Wonder walls: vertical greenery seeds urban biodiversity

    Vertical gardens on a mass scale could help bring temperatures down in cities and boost biodiversity. Until now, “living walls” were novelty features on landmark buildings, but an innovative Austro-German living wall could pave the way to delivering greener urbanisation worldwide.

  • The programmers reconstructing faces and reducing stress for disfigured patients

    People disfigured in accidents, war or from cancer have to wait months for an artificial nose or ear. So, a team of robotics developers at Portuguese company, μRoboptics, has stepped in to find a faster way to rebuild damaged faces with 3D printed prostheses.

  • Satellite

    Space satellites to connect the world’s cars and robots

    Low earth orbit (LEO) satellites hit the news when Elon Musk offered them to Ukraine to allow residents to keep communicating with the outside world when existing telecommunications networks were knocked out. But that’s only a small illustration of what LEO satellites can do for humanity if a Korean-led research team has its way, reports Sarah Morris.

  • Hitting the right targets: DNA test reveals if cancer patients will respond to chemotherapy treatments

    It is almost a flip of a coin whether pancreatic cancer patients respond to the standard chemotherapy drug, FOLFIRINOX. As a solution to oncologists apprehensively giving patients one of the toughest chemotherapy treatments out there, Dutch bioinformatics company, Omnigen, is developing a clinical decision support system based on a DNA test that shows a patient’s responsiveness to FOLFIRINOX treatment with an initial accuracy rate of 93%.

See more articles

Were you inspired by one of our articles and have a project idea you want to realise?

Through our funding programmes, national/regional funding bodies support SMEs, large companies, universities and research organisations conducting R&D and innovation projects together beyond borders to achieve great results.

Learn more about our programmes and discover whether we have a funding opportunity for your organisation.

Our open calls